- Previously, UCPMP for Pharma industry was issued in 2014, which was voluntary in nature.
- Key highlights of the UCPMP 2024
- Information about drugs must be balanced, up-to-date, verifiable, must not mislead either directly or by implication.
- Claims and comparison: Brand names of products of other companies must not be used without prior consent.
- Comparisons of drugs must be factual, fair, and capable of substantiation.
- Textual and Audio-Visual Promotion: Promotional material such as mailings and journal advertisements must not be designed to disguise their real nature.
- Continuing Medical Education: Should only be allowed through a well-defined, transparent, and verifiable set of guidelines.
- Relationship with healthcare professionals: No gifts, monetary grants, pecuniary advantage, etc., should be offered.
- Ethics Committee for Pharma Marketing Practices: In each association for handling complaints.
- Other provisions: Department of Pharmaceuticals may issue standing orders for removal of difficulties in operation of UCPMP.
- It shall also apply mutatis mutandis to medical devices unless exempted, or to the extent modified by standing orders.
Need of UCPMP
|
